A carregar...
Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France
OBJECTIVES: To evaluate the cost-effectiveness of a new generation integrase inhibitor (INI), dolutegravir (DTG), in France, in treatment-experienced (TE) and INI-naïve HIV-infected adults with at least two classes resistance compared to raltegravir (RAL), by adapting previously published Anti-Retro...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4699888/ https://ncbi.nlm.nih.gov/pubmed/26714188 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0145885 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|